By Eric Schweibenz
On April 22, 2014, Chief ALJ Charles E. Bullock issued Order No. 4 in Certain Hemostatic Products and Components Thereof (Inv. No. 337-TA-913).

By way of background, the investigation is based on a February 28, 2014 complaint filed by Baxter International Inc., Baxter Healthcare Corp., and Baxter Healthcare SA of Switzerland alleging violation of Section 337 by Johnson & Johnson Inc., Ethicon, Inc., Ferrosan Medical Devices A/S, and Packaging Coordinators, Inc. in the importation into the U.S. and sale of certain hemostatic products and components thereof that infringe one or more claims of U.S. Patent Nos. 8,303,981; 8,512,729; 6,066,325; 8,357,378; and 8,603,511.  See our March 5, 2014 and April 4, 2014 posts for more details on the complaint and notice of investigation, respectively.

In the Order, ALJ Bullock set August 7, 2015 as the target date for completing the investigation (which is approximately sixteen months after institution of the investigation).  In addition, ALJ Bullock directed the parties to submit proposed procedural schedules by April 30, 2014.  ALJ Bullock further noted that the evidentiary hearing in this investigation will commence on January 5, 2015, for purposes of preparing proposed procedural schedules.